Project Grant R21AI185808
Award Date
5/13/25
Completion Date
4/30/27
Dollars Obligated
$233K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
North Carolina, USA
Similar Awards
This Project Grant award of $453,900.00 from the National Institute of Allergy and Infectious Diseases (NIAID) under CFDA 93.855 - Allergy and Infectious Diseases Research program supports research to develop a genome editing platform based on phage recombinases that can operate across a broad range of bacterial species, including clinically relevant pathogens. The award to the University of Rochester aims to transform genetic manipulation capabilities for bacteria by leveraging phage proteins...
This Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop a novel assay for targeted isolation of bacteriophages (phages) from environmental samples. The $173,030 award will be used to create a co-culture-based technique that can differentiate phages based on their infection dependencies, allowing for the preferential selection of phages that require specific...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $721,555 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Colorado-Denver to study horizontal gene transfer and transduction within intestinal microbiomes. The project aims to develop high-throughput methods for measuring and identifying transduction events that spread virulence and antibiotic resistance traits among bacterial pathogens and the broader...
This Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to optimize the regimen structure and characterize the pharmacokinetics and pharmacodynamics of a multi-phage cocktail therapy for treating extensively drug-resistant Pseudomonas aeruginosa infections. The $714,053 award, with a period of performance from August 2024 to July 2029, will fund the development of a...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $206,615 to Duke University to conduct genetic analysis and in vitro/in vivo studies on the human gut bacterium Phocaeicola vulgatus. The research aims to identify the molecular mechanisms this bacterium uses to efficiently colonize the mammalian gut, even in competition with other microbes. Key expected outcomes include...
This federal Project Grant award from the National Institutes of Health (NIH) Trans-NIH Research Support program (CFDA 93.310) provides $1,148,000.00 to The Trustees of Princeton University to develop novel approaches for combating bacterial infections and advancing phage therapy and host-directed interventions. The project aims to leverage Princeton's breakthrough single-cell RNA sequencing technology, M3-SEQ, to gain unprecedented insight into host-pathogen interactions and identify new...
This $2,093,289 Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to advance the genetic engineering and axenic growth of two tick-borne rickettsial pathogens, Ehrlichia chaffeensis and Anaplasma phagocytophilum. The research aims to: 1) Optimize HIMAR1 mutagenesis to develop a comprehensive mutational library for E. chaffeensis; 2) Expand targeted mutation...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,000,000 Project Grant to Phagepro, Inc., a minority-owned and woman-owned small business, under the Allergy and Infectious Diseases Research program (CFDA 93.855). This 3-year grant, with a project period from December 16, 2024, to May 31, 2027, supports the development of a prophylactic cholera phage cocktail. Phagepro, which specializes in bacteriophage-based solutions for infectious disease prevention and...
This federal Project Grant award, provided by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the "Discovery and Applied Research for Technological Innovations to Improve Human Health" program (CFDA 93.286), aims to develop an adaptive framework to rapidly synthesize and reconfigure synthetic bacteriophages (phages) to counter antibiotic-resistant pathogens. The $128,461 award will fund research to optimize an E. coli cell-free system to produce phages...
This $367,059 federal Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) supports research to develop a better understanding of the genomic, epigenomic, and transcriptomic outcomes of gene therapy. The research aims to explore the long-term effects of vector integration, the impact of cell/tissue type and promoters on vector behavior, and the host response to different gene therapy delivery...